DCK and acute myeloid leukemia: We tested the hypothesis that the analysis of drug targets for polymorphism can help to establish gene-based information for the treatment of AML patients; we investigated functional SNPs in the CDA and dCK genes and found that some polymorphisms have a role in predicting survival and toxicity.